Key result
AAV9-mediated PDE4B gene therapy prevents systolic dysfunction and adverse remodeling in murine heart failure.
Why the study?
PDE4B deficiency impairs Ca2+ handling and PDE4B decreases in pressure overload hypertrophy, suggesting increasing cardiac PDE4B may be beneficial in heart failure.
Does cardiac overexpression of PDE4B prevent maladaptive remodeling and systolic dysfunction in heart failure models?
Population
Human cardiac tissues and mouse models of heart failure
Comparison
Cardiomyocyte-specific PDE4B overexpression vs control
Design
Preclinical animal and human tissue study
Authors
Loading...
PDE4B overexpression merits exploration as a heart failure target; leaves open translation from mouse models to clinical use.
Does cardiac overexpression of PDE4B prevent maladaptive remodeling and systolic dysfunction in heart failure models?
Moderate cardiac overexpression of PDE4B via gene therapy is cardioprotective and prevents maladaptive remodeling in mouse models of heart failure.
Karam et al. (2020) studied Heart failure. PDE4B overexpression vs. Control was evaluated on Cardiac remodeling, systolic dysfunction, hypertrophy, apoptosis, and fibrosis. Moderate overexpression of PDE4B via AAV9 gene therapy prevented systolic dysfunction, apoptosis, and fibrosis, and attenuated hypertrophy in mouse models of heart failure.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: